SAFETY/EFFICACY OF IV ANTI-D FOR TREATMENT OF THROMBOCYTOPENIA IN HCV

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这将是一项前瞻性初步研究，旨在评估在HIV阳性和HIV阴性患者中，在丙型肝炎感染治疗（基于聚乙二醇干扰素的治疗）之前或期间，静脉注射抗D治疗显著血小板减少症的安全性和疗效。 假设：静脉注射抗D抗体将使血小板计数增加至超过聚乙二醇干扰素治疗开始时推荐的阈值50，000/uL。 静脉注射抗-D将使血小板计数增加至超过聚乙二醇干扰素治疗剂量减少时推荐的阈值50，000/uL。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This will be a prospective pilot study of the safety and efficacy of intravenous Anti-D for the treatment of significant thrombocytopenia prior to or during the treatment of hepatitis C infection (with peginterferon-based therapy) in HIV-positive and HIV-negative patients. Hypothesis: Intravenous anti-D will increase platelet counts above the threshold of 50,000/uL recommended for the initiation of peginterferon therapy. Intravenous Anti-D will increase platelet counts above the threshold of 50,000/uL recommended for the dose reduction of peginterferon therapy.